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Background: Influenza A(H1N1)pdm09, A(H3N2) and 
B viruses were co-circulating in Europe between 
September 2019 and January 2020. Aim: To provide 
interim 2019/20 influenza vaccine effectiveness (VE) 
estimates from six European studies, covering 10 
countries and both primary care and hospital settings.
Methods: All studies used the test-negative design, 
although there were some differences in other study 
characteristics, e.g. patient selection, data sources, 
case definitions and included age groups. Overall and 
influenza (sub)type-specific VE was estimated for each 
study using logistic regression adjusted for potential 
confounders. Results: There were 31,537 patients 
recruited across the six studies, of which 5,300 (17%) 
were cases with 5,310 infections. Most of these (4,466; 
84%) were influenza A. The VE point estimates for all 
ages were 29% to 61% against any influenza in the 
primary care setting and 35% to 60% in hospitalised 
older adults (aged 65 years and over). The VE point 
estimates against A(H1N1)pdm09 (all ages, both set-
tings) was 48% to 75%, and against A(H3N2) ranged 
from −58% to 57% (primary care) and −16% to 60% 
(hospital). Against influenza B, VE for all ages was 62% 
to 83% (primary care only). Conclusions: Influenza 
vaccination is of continued benefit during the ongoing 
2019/20 influenza season. Robust end-of-season VE 
estimates and genetic virus characterisation results 
may help understand the variability in influenza (sub)
type-specific results across studies.
Introduction
All European Union (EU) countries and the United 
Kingdom (UK) recommend seasonal influenza vaccine 
for older adults and those at increased risk of influ-
enza complications and severe disease, as well as for 
patients with chronic conditions [1]. In addition, uni-
versal childhood influenza is available in some coun-
tries in the World Health Organization (WHO) European 
Region, and was introduced incrementally in the UK in 
2013/14 [2].
The 2019/20 northern hemisphere influenza season 
WHO trivalent influenza vaccine strains recommenda-
tions were for an A/Brisbane/02/2018 (H1N1)pdm09-
like virus, an A/Kansas/14/2017(H3N2)-like virus and 
a B/Colorado/06/2017-like virus (B/Victoria lineage) 
[3]. Quadrivalent vaccines were recommended to also 
include a B/Phuket/3073/2013-like virus (B/Yamagata 
lineage) [4].
The 2019/20 influenza season started early in most 
countries of the WHO European Region, with influenza 
A(H1N1)pdm09 and A(H3N2) virus subtypes, as well as 
influenza B circulating throughout the region, although 
predominantly influenza A overall (69%) [5]. Despite 
this, some countries reported dominance of influenza 
B, with a few reporting co-dominance [5].
The I-MOVE (Influenza – Monitoring Vaccine 
Effectiveness in Europe) network has measured 
influenza vaccine effectiveness (VE) annually since 
2008/09, with its partners including Denmark, Spain, 
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the UK and many EU countries measuring VE through 
the I-MOVE multicentre studies. We summarise interim 
influenza VE estimates for the 2019/20 season from six 
studies (four single-country and two multi-country), 
with out- and in-patient (hospital) settings, in order to 
provide information for measures of influenza preven-
tion and control for the remaining season. Results pre-
sented here also helped to inform the February 2020 
WHO Vaccine Strain Selection Committee.
Methods
Study setting
The four primary care (PC) studies were conducted in 
Denmark (DK-PC), Spain (ES-PC), the UK (UK-PC) and 
through the EU I-MOVE multi-country network (EU-PC; 
eight of nine participating countries in this network 
having available data for interim analysis). The two hos-
pital setting (H) studies were in Denmark (DK-H) and 
through the EU I-MOVE multi-country network (EU-H; 
two of 11 participating countries in this network having 
available data for interim analysis) (Figure 1). In total, 
10 countries contributed data to the interim influenza 
vaccine effectiveness results presented in this article.
Study design
The methods for all six studies have already been 
described [6-10]. The test-negative design [11] was 
used in all studies, although some studies varied in 
their patient selection and/or data collection (Table 
1). Briefly, patients presenting to participating primary 
care settings with symptoms of influenza-like illness 
(ILI) or acute respiratory infection (ARI) were swabbed. 
For the hospital setting swabs were taken from those 
with symptoms of severe ARI (SARI). Three studies 
used an exhaustive or systematic selection of patients 
to swab (EU-H, ES-PC and EU-PC), while physicians’ dis-
cretion was used to select patients for swabbing in the 
others (DK-H, DK-PC and UK-PC). Samples were tested 
by reverse transcription (RT)-PCR for generic influenza 
virus detection, type A subtyping and type B lineage 
determination. Cases were defined as patients with 
positive results by influenza virus (sub)type. Controls 
were defined as those with negative results.
Figure 1




EU-PC, EU-H and ES-PC
EU-PC
EU-PC AND EU-H
DK-PC/DK-H: Denmark primary care and hospital studies; ES-PC: Spain primary care study; EU-H: European Union hospital-based multi-country 
I-MOVE study; EU-PC: European Union primary care-based multi-country I-MOVE study; I-MOVE: Influenza - Monitoring Vaccine Effectiveness in 
Europe; UK-PC: United Kingdom primary care study.
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Vaccinated patients were defined as those having had 
the 2019/20 influenza vaccine at least 14 days before 
onset of symptoms (15 days for two studies: EU-PC and 
EU-H). Those vaccinated less than 14 days (less than 15 
days for two studies) before symptom onset, or with 
unknown date of vaccination were excluded.
Most study countries (six from EU-PC and Denmark) 
selected all or a random sample of influenza virus-pos-
itive specimens for haemagglutinin genome segment 
and/or whole genome sequencing. This was followed 
by phylogenetic analysis to determine clade distribu-
tion for potential impact on VE. In Spain, the ES-PC 
study (regions not included in EU-PC) sequenced an ad 
hoc sample of influenza viruses. In UK-PC, sequencing 
is done by two contributing surveillance schemes. One 
of these sequences all influenza viruses with sufficient 
genetic material (Ct value < 31) and all viruses derived 
from vaccinated cases. The other one sequences a 
subset only. Sequencing results were provided for both 
studies in Denmark together (DK-PC and DK-H).
Ethical statement
The planning, conduct and reporting of the stud-
ies was in line with the Declaration of Helsinki [12]. 
Official ethical approval and patient consent was not 
required for DK-H and DK-PC according to Danish reg-
ulations, nor for EU-PC (the Netherlands and Spain) 
and UK-PC, as these studies were classified as being 
part of routine care/surveillance. Other study sites 
obtained local ethical approval from a national review 
board, according to local site regulations, as follows: 
EU-H (Aragon: approved 20 November 2019 by the 
CEIC Aragon, no registration number given; Granada: 
approved 11 October 2019 by the CEIM/CEI Provincial 
de Granada, no registration number given; Navarra: 
2018/95; Romania: CE353/30.09.2019); EU-PC (France: 
471393; Germany: EA2/126/11; Ireland: ICGP2019.4.04; 
Portugal: approved 18 January 2012 by the Ethics 
Committee of Instituto Nacional de Saúde Doutor 
Ricardo Jorge, no registration number given; Romania: 
CE354/30.09.2019; Sweden: 2006/1040–31/2).
Statistical analysis
Each study computed VE by subtracting the ratio of the 
odds of vaccination in cases and controls from one, 
as a percentage (VE = (1 – odds ratio (OR) x 100%). All 
studies applied logistic regression to adjust their VE 
for measured confounding variables (Table 1). Study-
specific VE was estimated overall and where possible, 
by age group and target population (as defined locally 
in the various studies and study sites) against influenza 
A overall, A(H1N1)pdm09, A(H3N2), influenza B and B/
Victoria. For analyses with a small sample size, defined 
as those having fewer than 10 cases or controls per 
parameter, a sensitivity analysis was performed using 
Firth’s method of penalised logistic regression (PLR) to 
assess small sample bias [13,14]. We considered a dif-
ference of > 10% between the PLR and original estimate 
to be an indication of small sample bias, and any such 
estimates were not included.
Results
From 30 September 2019 to 29 January 2020, in the pri-
mary care setting, there were 12,842 patients included 
in the DK-PC study (1,723 cases), 1,798 in ES-PC (955 
cases), 2,987 in EU-PC (1,052 cases) and 2,548 in 
UK-PC (782 cases). In the hospital setting, there were 
10,761 in DK-H (659 cases) and 601 in EU-H (129 cases).
Overall, 84% (4,466/5,310) of confirmed infections were 
influenza A virus-positive and 16% (844/5,310) were 
influenza B virus-positive, noting that the previously 
mentioned total refers to patients rather than infec-
tions. The proportion of subtyped influenza A viruses 
was 93% to 98% in EU-H, ES-PC, EU-PC and UK-PC, and 
45% to 51% in DK-H/DK-PC. Most subtyped influenza 
A viruses were influenza A(H1N1)pdm09 (67–89%) in 
ES-PC, EU-PC and EU-H; this subtype comprised 46% 
to 47% in DK-PC/DK-H and 7% in UK-PC (Figure 2). The 
proportion of influenza B viruses ranged from 4% in 
UK-PC to 30% in ES-PC (Figure 2). The proportion of B 
viruses ascribed to a lineage was 27% overall (100% 
for EU-H, 70% for EU-PC, 23% for UK; lineage informa-
tion not available in DK-PC, DK-H and ES-PC studies). 
Most of those that were ascribed to a lineage were B/
Victoria: 98% in EU-PC, 75% in UK and 67% in EU-H.
All influenza (A and B)
Primary care settings
For all ages, VE against laboratory-confirmed influenza 
(both A and B combined) ranged from 29% (95% con-
fidence interval (CI): 4 to 48) in UK-PC to 61% (95% CI: 
37 to 76) in ES-PC. The VE against all influenza among 
children aged 0 to 17 years was 64% (95% CI: 16 to 85) 
in EU-PC and 95% (95% CI: 67 to 99) in DK-PC. For those 
aged 0 to 14 years in ES-PC, VE was 67% (95% CI: 18 
to 87), while for those aged 2 to 17 years in UK-PC, VE 
was 37% (95% CI: −21 to 67). For patients aged 18 to 64 
years, VE ranged from 36% (95% CI: 1 to 58) in UK-PC to 
58% (95% CI: 43 to 69) in DK-PC. For those aged 15 to 
64 years in ES-PC, VE was 55% (95% CI: 10 to 77) (Table 
2). In ES-PC and EU-PC target groups for influenza vac-
cination, VE was 60% (95% CI: 22 to 79) and 53% (95% 
CI: 26 to 70), respectively.
Hospital settings
For all ages, VE against all laboratory-confirmed hospi-
talised influenza was 40% in DK-H (95% CI: 27 to 51). 
In older adults (aged at least 65 years), VE was 35% 




The VE against laboratory-confirmed influenza A for all 
ages ranged from 30% (95% CI: 4 to 49) in UK-PC to 
60% (95% CI: 34 to 76) in ES-PC. The VE against influ-
enza A among adults under 65 years ranged from 38% 
(95% CI: 3 to 60) in UK-PC (18–64-year-olds) to 62% 
(95% CI: 20 to 82) in the ES-PC study (15–64-year-olds). 
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Table 1
Summary of methods for the six European interim influenza vaccine effectiveness studies, influenza season 2019/20 












30 September 2019–25 
January 2020
1 October 2019–12 
January 2020
1 October 2019–29 
January 2020
2 December 2019–26 
January 2020
Setting Primary care Primary care Primary care Primary care Hospital Hospital
Location Denmark
Spain: Sentinel 
networks in 16 
of 19 regions
France, Germany, 
Ireland, the Netherlands, 
Portugal, Romania, Spain 
and Sweden
England, Scotland, 
Northern Ireland and 
Wales
Denmark
Spain: six hospitals in 
three regions; Romania: 
three hospitals



















Data linkage of 
Danish Microbiology 
Database, the Danish 
Vaccination Register 
and the Danish 
National Discharge 
Register
Hospital charts, vaccine 
registers, interviews 
with GPs, laboratory
Age groups of 
study population ≥ 6 months ≥ 6 months All ages
b All ages ≥ 6 months ≥ 65 years
Case definition





EU ILIc EU ILIc
ILI: Patient presenting 
in primary care with 
an acute respiratory 
illness with physician 
diagnosed fever, and 
with onset in the 
previous 7 days
ARI: Sudden onset 
of symptoms with 














used nationally or 
in the studye,f
In the study: 
99.5% QIV, 0.5% 
cell-propagated 
QIV
In Spain: 81.8% 
TIV, 10.3% QIV 
and 7.8% cell-
propagated QIV
In the study among 
controls: 
 
5% TIV; 2% adjuvanted 
TIV; 53% QIV; 1% LAIV4; 
0% cell-propagated QIV 
(one person vaccinated 
among controls), 38% 
unknown
In the study among 
controlsg: 7% LAIV4; 
12% cell-propagated 
QIV, 14% QIV, 22% 
adjuvanted TIV; 44% 
unknown
In the study: 99.5% 
QIV, 0.5% cell-
propagated QIV
In the study among 
controls: 100% TIV; 
22% adjuvanted TIV; 








calendar time as 
month (Oct-Jan)
Age (modelled 








Age (modelled as RCS, 
age group or linear 
term depending on 
analysis), sex, presence 




date (RCS) and study site
Age group, sex, 
month of onset, 
surveillance scheme, 
risk group
Age group, sex, 
presence of chronic 
conditions, calendar 
time as month (Oct-Jan)
Age (modelled as 
RCS or linear term 
depending on analysis), 





date (RCS or onset 
month depending on 
analysis) and study site
ARI: acute respiratory infection; DK-H: Denmark hospital study; DK-PC: Denmark primary care study; ES-PC: Spain primary care study; EU: European Union; EU-H: 
EU hospital multicentre I-MOVE study; EU-PC: EU primary care multicentre I-MOVE study; GP: general practitioner; ILI: influenza-like illness; I-MOVE: Influenza 
– Monitoring Vaccine Effectiveness in Europe; LAIV4: quadrivalent live attenuated influenza vaccine; LRI: lower respiratory infection; QIV: quadrivalent 
inactivated influenza vaccine; RCS: restricted cubic spline; SARI: severe acute respiratory infection; TIV: trivalent inactivated influenza vaccine; TND: test-
negative design; UK-PC: United Kingdom primary care study.
a 235 of 813 sentinel physicians included in ES-PC were also included in EU-PC.
b Patients < 6 months should have been excluded from the study, however the age group is specified as ‘all ages’ as age in months could not be verified from the 
data.
c EU ILI: Sudden onset of symptoms AND at least one of the following four systemic symptoms: fever or feverishness, malaise, headache, myalgia AND at least 
one of the following three respiratory symptoms: cough, sore throat, shortness of breath.
d EU SARI: Hospitalised person with one or more of: fever/feverishness, malaise, headache, myalgia, deterioration of general condition (asthenia, weight loss, 
anorexia, confusion/dizziness) AND one or more respiratory symptom (cough, sore throat or shortness of breath) at admission or within 48 hours.
e Vaccines were prepared from egg-propagated vaccine viruses, non-adjuvanted and administered intramuscularly unless otherwise specified.
f Where indicated, vaccine coverage among controls were used as representative of the source population from which the cases arose.
g UK vaccine strategy: 2–17 years of age: LAIV4 or QIV; 18–64 years of age: QIV or cell-propagated QIV; ≥ 65  years of age: adjuvanted TIV or cell-propagated QIV.
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In children less than 18 years of age, the VE ranged 
from 39% (95% CI: -19 to 69) in UK-PC (2–17-year-olds) 
to 95% (95% CI: 63 to 99) in DK-PC (0–17-year-olds) 
(Table 2).The VE in EU-PC and ES-PC target groups for 
influenza vaccination was 49% (95% CI: 16 to 69) and 
62% (95% CI: 24 to 82), respectively.
Hospital settings
For all ages, VE against laboratory-confirmed hospital-
ised influenza A was 41% (95% CI: 27 to 52) in DK-H. 
For older adults, VE was 37% (95% CI: 19 to 50) in DK-H 
and 62% (95% CI: 41 to 76) in EU-H.
Influenza A(H1N1)pdm09
Primary care settings
For all ages, VE against laboratory-confirmed influenza 
A(H1N1)pdm09 ranged between 48% (95% CI: 18 to 
68) in EU-PC and 75% (95% CI: 57 to 86) in DK-PC. The 
number of vaccinated cases in the UK-PC study was too 
small to provide a VE estimate.
The VE among children less than 18 years of age was 
46% (95% CI: −51 to 80) in EU-PC (0–17 years) and 51% 
(95% CI −45 to 83) in ES-PC (0–14 years). Among adults 
less than 65 years, VE was between 49% (95% CI: 1 to 
74) in EU-PC (18–64 years) and 68% (95% CI: 28 to 86) 
in ES-PC (15–64 years). VE for adults aged 65 years and 
older was 79% (95% CI: 37 to 93) in the DK-PC study. 
Target groups in the ES-PC had VE of 73% (95% CI: 40 
to 88) against influenza A(H1N1)pdm09.
Hospital settings
For hospitalised patients aged 65 years and older, VE 
was 51% (95% CI: 4 to 75) in DK-H and 63% (95% CI: 
40 to 77) in the EU-H study (Table 2). For hospitalised 
patients in DK-H aged 18 to 64 years, VE was 55% (95% 
CI: 3 to 79).
Virological results
Among the 212 A(H1N1)pdm09 viruses sequenced, 90% 
(n = 190) belonged to genetic clade 6B.1A5A (Table 3) 
and none belonged to the same clade as the vaccine 
component (6B.1A1). Twenty viruses (9%) belonged 
to the 6B.1A5B clade and one virus (1%) each to the 
6B.1A6 and 6B.1A7 clades.
Influenza A(H3N2)
Primary care settings
For patients of all ages, VE against influenza A(H3N2) 
ranged from −58% (95% CI: −338 to 43) in ES-PC to 
57% (95% CI: 27 to 75) in EU-PC. For children aged 2 to 
17 years in the UK-PC, VE was 39% (95% CI: −21 to 69). 
For those aged 18 to 64 years, VE was between 29% 
(95% CI: −19 to 57) in DK-PC and 71% (95% CI: 37 to 
87) in EU-PC. VE ranged from 12% (95% CI: −53 to 49) 
in DK-PC to 21% (95% CI: −56 to 60) in UK-PC in those 
aged 65 years and over. For target groups in the EU-PC, 
VE against influenza A(H3N2) was 38% (95% CI: −21 to 
69) (Table 2).
Hospital settings
VE among hospitalised patients aged 65 years and 
older against influenza A(H3N2) was between −16% 
(95% CI: −80 to 25) in DK-H and 60% (95% CI: −69 to 
90) in EU-H (Table 2).
Virological results
Of the 334 influenza A(H3N2) viruses sequenced, 
69% (n = 231) belonged to the same genetic clade as 
the vaccine strain (3C.3a), 20% (n = 67) belonged to 
3C.2a1b + T131K, 6% to 3C.2a1b + T135K-A (n = 21) and 
5% to 3C.2a1b + T135K-B (n = 15). The distribution of 
(sub)clades varied by country, e.g. from 46% (n = 31) in 
DK-H/DK-PC to 89% (n = 150) in UK-PC for clade 3C.3a, 




Sample sizes for influenza B were large enough to esti-
mate VE in three studies in the primary care setting only 
(DK-PC, ES-PC and EU-PC). The VE against laboratory-
confirmed influenza B for all age groups ranged from 
62% (95% CI: 17 to 83) in EU-PC to 83% (95% CI: 51 to 
94) in DK-PC. For those aged 18–64 years, VE was 12% 
in EU-PC (95% CI: −135 to 67) (Table 2). VE against B/
Victoria was 60% (95% CI: −12 to 86) (only estimated 
for EU-PC). The number of cases of B/Yamagata was 
too low for VE to be estimated.
Virological results
Of the 59 influenza B/Victoria viruses sequenced, 
58 belonged to subgroup 1A(del162–164)B and one 
belonged to the vaccine subclade 1A(del162–163).
Sensitivity analyses
Results with small sample sizes were subject to sensi-
tivity analyses, all of which gave similar results (abso-
lute difference range: 1–6%).
Discussion
Our results for the 2019/20 influenza season in six well-
known influenza studies across Europe indicate that 
interim VE against any laboratory-confirmed influenza 
among all ages in primary care and hospital settings 
ranged between 29% and 61%, while VE was from 53% 
to 60% in vaccination target groups. The proportions 
of influenza (sub)types contributing to these overall 
results varied considerably by study.
Against influenza A (all subtypes) among all ages, 
point estimates for VE ranged between 30% and 
60% in both types of settings, and they were slightly 
higher (49–62%) in the target groups for vaccination. 
Against influenza A(H1N1)pdm09, VE point estimates 
among all ages ranged from 48% to 75%, being slightly 
higher among older adults (aged 65 years and older) in 
DK-PC at 79% and slightly lower in children aged 0 to 
17 years in EU-PC (46%). There were varied results for 
VE against influenza A(H3N2). For patients of all ages 
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combined, two studies (one primary care, one hospi-
tal) had VE point estimates < 0%, two (primary care) 
had VE < 30%, and two (one primary care, one hospital) 
had VE > 50%. The VE point estimate against A(H3N2) 
was highest among 18 to 64-year-olds in EU-PC (71%). 
Against laboratory-confirmed influenza B, VE among all 
ages ranged from 62% to 83% in primary care settings.
The VE point estimates against all influenza from three 
of four primary care studies (DK-PC, ES-PC and EU-PC) 
over all ages, at 53% to 61%, are similar to VE point 
estimates from Canada (58%) [15], and a little higher 
than those reported from the United States (US) (45%) 
[16], noting that proportions of influenza (sub)types 
and proportions of study participants contributing to 
age groups may be slightly different across all stud-
ies. For older adults (aged 65 years and over), the six 
studies presented here had VE point estimates of 43% 
to 66% across all settings. This is similar to estimates 
from Finland, Sweden and Canada for this age group, 
at 41% [17], 44% [18] and 60% [15], respectively. It is 
also similar for those aged 50 years and over in the 
US, at 43% [16], noting that underlying proportions of 
influenza (sub)types are likely to be different across all 
studies.
The 2019/20 interim VE against influenza A(H1N1)
pdm09 was higher compared with the 2018/19 interim 
season estimates in most studies among all ages, 
except for the EU-PC study [19]. The VE against A(H1N1)
pdm09 was also higher among those aged 65 years 
and older in the hospital-based studies in the 2019/20 
season compared with the previous season [19]. The 
main circulating genetic clade in the 2019/20 stud-
ies is 6B.1A5A and to a lesser extent, 6B.1A5B, which 
although different from the vaccine strain, show good 
reactivity with ferret antiserum raised against the vac-
cine virus [20]. The 2019/20 interim influenza A(H1N1)
Figure 2
Proportion of influenza virus (sub)types among cases, six European studies, interim influenza season 2019/20 (n = 5,310)
A(H1N1)pdm09 A(H3N2) A unsubtyped B/Victoria B/Yamagata B lineage unknown
Study (n)




















DK-H: Denmark hospital study; DK-PC: Denmark primary care study; ES-PC: Spanish primary care study; UK-PC: United Kingdom primary care 
study; EU-H: European Union hospital multicentre I-MOVE study; EU-PC: European Union primary care multicentre I-MOVE study; I-MOVE: 
Influenza - Monitoring Vaccine Effectiveness in Europe.
a 246 of influenza A(H1N1)pdm09, eight A(H3N2) and 79 B cases are also in ES-PC.
b Includes three co-infections. These, and two patients from one site, were not included in the A(H3N2) analysis, but in the ‘any influenza A’ 
analysis.
c Includes 12 co-infections.
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Table 2a
Interim vaccine effectiveness (VE) against all laboratory-confirmed influenza, influenza A, A(H1N1)pdm09, A(H3N2) and 
B, by age group, target group for vaccination and by study, six European studies, influenza season 2019/20
Influenza (sub)type and study Setting Study populationa
Cases Controls
VEb 95% CI
All Vacc % All Vacc %
All influenza (A and B)
DK-PCc PC
All ages 1,715 119 7 11,127 1,349 12 56 46 to 65
0–17 years 669 1 < 1 3,793 669 18 95 67 to 99
18–64 years 862 48 6 5,436 480 9 58 43 to 69
≥ 65 years 184 70 38 1,898 808 43 40 18 to 57
ES-PC PC
All ages 955 46 5 843 79 9 61 37 to 76
0–14 years 416 14 3 298 15 5 67 18 to 87
15–64 years 513 19 4 473 27 6 55 10 to 77
Target groupd 105 27 26 181 57 31 60 22 to 79
EU-PC PC
All ages 1,052 76 7 1,935 211 11 53 34 to 67
0–17 years 419 12 3 810 28 4 64 16 to 85
18–64 years 566 33 6 920 81 9 51 21 to 70
Target groupd 197 52 26 509 158 31 53 26 to 70
UK-PC PC
All ages 782 114 15 1,766 308 17 29 4 to 48
2–17 years 303 24 8 358 28 8 37 −21 to 67
18–64 years 379 44 12 937 119 13 36 1 to 58
≥ 65 years 72 46 64 281 161 57 26 −44 to 62
DK-Hc H
All ages 658 168 26 10,103 2,745 27 40 27 to 51
18–64 years 237 30 13 3,397 533 16 48 22 to 65
≥ 65 years 315 134 43 5,008 2,166 43 35 17 to 49
EU-Hc H ≥ 65 years 128 54 42 473 312 66 60 39 to 74
Influenza A
DK-PC PC
All ages 1,540 115 8 11,127 1,349 12 54 43 to 63
0–17 years 579 1 < 1 3,793 61 2 95 63 to 99
18–64 years 786 47 6 5,436 480 9 54 38 to 67
≥ 65 years 175 67 38 1,898 808 43 41 18 to 57
ES-PC PC
All ages 670 40 6 843 79 9 60 34 to 76
0–14 years 244 12 5 298 15 5 48 −39 to 81
15–64 years 400 15 4 473 27 6 62 20 to 82
Target groupd 90 23 26 181 57 31 62 24 to 82
EU-PC PC
All ages 746 67 9 1,906 210 11 53 32 to 67
0–17 years 261 10 4 800 28 4 53 −19 to 81
18–64 years 426 27 6 903 81 9 60 32 to 76
Target groupd 161 46 29 503 157 31 49 16 to 69
UK-PC PC
All ages 756 110 15 1,766 308 17 30 4 to 49
2–17 years 294 23 8 358 28 8 39 −19 to 69
18–64 years 364 42 12 937 119 13 38 3 to 60
≥ 65 years 70 45 64 281 161 57 24 −49 to 61
DK-H Hospital
All ages 629 162 26 10,103 2,745 27 41 27 to 52
18–64 years 226 29 13 3,397 533 16 47 21 to 65
≥ 65 years 306 129 42 5,008 2,166 43 37 19 to 50
EU-Hc Hospital ≥ 65 years 122 50 41 473 312 66 62 41 to 76
CI: confidence interval; DK-PC: Denmark primary care study; DK-H: Denmark hospital study; ES-PC: Spain primary care study; EU-H: European 
Union hospital multicentre I-MOVE study; EU-PC: European Union primary care multicentre I-MOVE study; I-MOVE: Influenza - Monitoring 
Vaccine Effectiveness in Europe; LAIV4: quadrivalent live attenuated influenza vaccine; NC: not calculated (percentages not shown where 
denominators < 60); PC: primary care; UK-PC: United Kingdom primary care study; Vacc: vaccinated; VE: vaccine effectiveness.
Countries included in EU-H analysis for any influenza, influenza A and influenza A(H3N2): Romania and Spain. For analysis against influenza 
A(H1N1)pdm09: Spain only.
Countries included in EU-PC analysis for all influenza, influenza A and A(H1N1)pdm09: France, Germany, Ireland, the Netherlands, Portugal, 
Romania, Spain and Sweden. For analysis against influenza A(H3N2): France, Germany, Ireland, the Netherlands, Romania, Spain and 
Sweden are included. For analysis against influenza B: France, Germany, Ireland, Portugal, Romania, Spain and Sweden. For analysis 
against influenza B/Victoria: France, Germany, Ireland, Portugal, Romania and Sweden.
a Age-specific or target group-specific VE was not included for overall or (sub)type-specific VE in some study sites, where sample size did not 
allow estimation of VE.
b For details of adjustment variables, see Table 1.
c Some records with missing values were dropped from this analysis.
d Groups targeted by seasonal influenza vaccination as defined locally in the studies and study sites.
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Influenza (sub)type and study Setting Study populationa
Cases Controls
VEb 95% CI
All Vacc % All Vacc %
Influenza A(H1N1)pdm09
DK-PC PC
All ages 373 14 4 11,127 1,349 12 75 57 to 86
18–64 years 229 10 4 5,436 480 9 67 38 to 83
≥ 65 years 28 4 NC 1,898 808 43 79 37 to 93
ES-PC PC
All ages 566 30 5 843 79 9 69 46 to 82
0–14 years 198 10 5 298 15 5 51 −45 to 83
15–64 years 349 12 3 473 27 6 68 28 to 86
Target groupd 76 17 22 181 57 31 73 40 to 88
EU-PC PC
All ages 487 33 7 1,906 210 11 48 18 to 68
0–17 years 172 9 5 786 27 3 46 −51 to 80
18–64 years 292 14 5 903 81 9 49 1 to 74
DK-H Hospital
All ages 132 22 17 10,103 2,745 27 54 24 to 72
18–64 years 68 8 12 3,397 533 16 55 3 to 79
≥ 65 years 44 12 NC 5,008 2,166 43 51 4 to 75
EU-Hc Hospital ≥ 65 years 98 42 43 445 303 68 63 40 to 77
Influenza A(H3N2)
DK-PC PC
All ages 418 45 11 11,127 1,349 12 27 −4 to 49
18–64 years 190 17 9 5,436 480 9 29 −19 to 57
≥ 65 years 55 27 NC 1,898 808 43 12 −53 to 49
ES-PC PC All ages 75 10 13 799 79 10 −58 −338 to 43
EU-PC PC
All ages 244 33 14 1,772 180 10 57 27 to 75
18–64 years 125 12 10 834 75 9 71 37 to 87
Target groupd 70 28 40 431 126 29 38 −21 to 69
UK-PC PC
All ages 675 103 15 1,766 308 17 25 −3 to 46
2–17 years 273 22 8 358 28 8 39 −21 to 69
18–64 years 308 38 12 937 119 13 31 −8 to 56
≥ 65 years 66 43 65 281 161 57 21 −56 to 60
DK-H Hospital
All ages 154 59 38 10,103 2,745 27 −13 −58 to 19
≥ 65 years 89 53 60 5,008 2,166 43 −16 −80 to 25
EU-Hc Hospital ≥ 65 years 12 4 NC 313 199 64 60 −69 to 90
Influenza B
DK-PC PC All ages 183 4 2 11,127 1,349 12 83 51 to 94
ES-PC PC All ages 285 6 2 843 79 9 66 7 to 87
EU-PC PC
All ages 305 9 3 1,373 169 12 62 17 to 83
18–64 years 138 6 4 658 64 10 12 −135 to 67
Influenza B Victoria
EU-PCc PC All ages 209 5 2 1,190 141 12 60 −12 to 86
CI: confidence interval; DK-PC: Denmark primary care study; DK-H: Denmark hospital study; ES-PC: Spain primary care study; EU-H: European 
Union hospital multicentre I-MOVE study; EU-PC: European Union primary care multicentre I-MOVE study; I-MOVE: Influenza - Monitoring 
Vaccine Effectiveness in Europe; LAIV4: quadrivalent live attenuated influenza vaccine; NC: not calculated (percentages not shown where 
denominators < 60); PC: primary care; UK-PC: United Kingdom primary care study; Vacc: vaccinated; VE: vaccine effectiveness.
Countries included in EU-H analysis for any influenza, influenza A and influenza A(H3N2): Romania and Spain. For analysis against influenza 
A(H1N1)pdm09: Spain only.
Countries included in EU-PC analysis for all influenza, influenza A and A(H1N1)pdm09: France, Germany, Ireland, the Netherlands, Portugal, 
Romania, Spain and Sweden. For analysis against influenza A(H3N2): France, Germany, Ireland, the Netherlands, Romania, Spain and 
Sweden are included. For analysis against influenza B: France, Germany, Ireland, Portugal, Romania, Spain and Sweden. For analysis 
against influenza B/Victoria: France, Germany, Ireland, Portugal, Romania and Sweden.
a Age-specific or target group-specific VE was not included for overall or (sub)type-specific VE in some study sites, where sample size did not 
allow estimation of VE.
b For details of adjustment variables, see Table 1.
c Some records with missing values were dropped from this analysis.
d Groups targeted by seasonal influenza vaccination as defined locally in the studies and study sites.
Table 2b
Interim vaccine effectiveness (VE) against all laboratory-confirmed influenza, influenza A, A(H1N1)pdm09, A(H3N2) and 
B, by age group, target group for vaccination and by study, six European studies, influenza season 2019/20
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pdm09 VE in Canada [15] and the US [16] was 44% and 
37%, respectively. These overall results are lower than 
the DK-PC and ES-PC results, but are more compara-
ble with the EU-PC results (48%). In the US, there was 
some indication of lower VE among younger adults (18–
49 years) with VE being 5% [16]. None of the studies 
reported in this article indicate a much lower A(H1N1)
pdm09 VE among younger adults. End-of-season over-
all results as well as clade/genetic variant-specific 
results and birth cohort-specific VE will help under-
stand differences between studies at international 
level.
Unlike observed estimates in the 2018/19 season, in 
which three of five studies reporting A(H3N2) cases 
had VE below zero and all were below 50% [19], two of 
six 2019/20 interim study results were below zero, two 
were between 25% and 50%, and two were between 
50% and 60%. The EU-PC and the ES-PC studies 
showed very different point estimates of A(H3N2) VE 
among all ages; however, there were only eight cases 
in common across these studies. There is consider-
able variation in the VE estimates against A(H3N2) 
presented here, which may go hand-in-hand with the 
considerable genetic diversity observed. While A(H3N2) 
viruses remain difficult to characterise antigenically 
[20], reports suggest that the 3C.3a circulating viruses 
were antigenically similar to the vaccine virus. While 
a higher VE against A(H3N2) among studies with high 
proportions of 3C.3a characterised viruses might be 
anticipated, this was not observed everywhere. The 
other viruses circulating belonged to the 3C.2a1b 
clade, most with additional substitutions. These 
viruses are more genetically distinct from the vaccine 
virus and therefore antigenically less similar. However, 
2019/20 interim VE from Canada against A(H3N2) was 
62%, and 94% of the 80 viruses sequenced in Canada 
belonged to the 3C.2a1b clade. While clade-specific VE 
estimates at the end of the 2019/20 season could elu-
cidate whether different circulating clades of A(H3N2) 
viruses across the region explain the differences in VE 
against A(H3N2) observed here in these studies, some 
of the observed differences in interim VE may indi-
cate that further explanations, such as immunological 
cohort effects [21], need to be investigated.
Recent vaccine seed A(H3N2) viruses have developed 
adaptions during propagation in eggs, potentially neg-
atively affecting VE [22]. Cell-propagated vaccines were 
used in some studies, but there was insufficient data 
to estimate vaccine type-specific VE.
VE against influenza B was > 60% among all ages in pri-
mary care, with a lower VE among those aged 18 to 64 
years in EU-PC. However, sample size was lower in this 
age group and the low VE may possibly be a result of 
random variation. The high overall VE was comparable 
with 2019/20 interim VE against influenza B in Canada 
(69%) [15]. In the US, overall VE against B/Victoria was 
lower, at 50% [16].
In studies where lineage was available, the vast major-
ity of circulating influenza B belonged to the B/Victoria 
lineage, which was the lineage included in the trivalent 
vaccine but of another subgroup. The quadrivalent vac-
cine was used widely in Europe, however because of 
low circulation of B/Yamagata viruses, the VE of quad-
rivalent and trivalent vaccines could not be compared in 
the context of VE against trivalent lineage-mismatched 
influenza B. Among the sequenced B/Victoria viruses, 
98% belonged to the subgroup 1A(del162–164)B, dif-
fering from the vaccine virus by a further amino acid 
deletion, and being antigenically different [3,23,24]. 
Nevertheless, human serology studies show some evi-
dence of cross-reactivity between the vaccine and the 
circulating B/Victoria viruses [20,23,24].
The early start of the season in most European coun-
tries included in these six studies [5] resulted in higher 
incidence and greater precision for interim VE estimates 
than in 2018/19, although some studies did have lower 
sample size for some subgroups in this interim analy-
sis. Each study used study-specific criteria to define 
if a sample size was too small to attempt to estimate 
VE. Where VE results were presented, and sample size 
was small, sensitivity analyses were used to address 
potential small sample bias where appropriate. End-
of-season estimates will have higher sample size and 
provide more robust estimates. Residual confounding 
and bias are known limitations potentially present in 
all observational studies.
Vaccination remains the key successful method of 
influenza prevention, with one to two-thirds of all vac-
cinated individuals receiving protection during the 
2019/20 influenza season. Promotion of influenza vac-
cination should be maintainted in line with national 
guidelines and recommendations in all European coun-
tries with ongoing influenza virus circulation. Given the 
variation in VE estimates against A(H3N2), it remains 
important that when national guidelines indicate neu-
raminidase inhibitors to be used, they are used regard-
less of vaccination status as prophylaxis and therapy 
where there is influenza A(H3N2) virus circulation to 
help prevent severe outcomes [1].
Bi-annual reports on influenza VE in prior and exist-
ing seasons are provided by the Global Influenza VE 
(GIVE) Collaboration. The February 2020 GIVE report 
included interim VE results presented here to help 
inform the WHO Vaccine Strain Selection Committee 
meeting of 24 to 27 February 2020 in Geneva. For the 
2020/21 northern hemisphere season, WHO provided 
specific recommendations for egg-based, cell-based 
and recombinant-based vaccines [25]. Compared with 
the northern hemisphere 2019/20 trivalent vaccine 
recommendations, all components for the 2020/21 
trivalent vaccine have been changed. For influenza 
A(H1N1)pdm09, WHO recommended A/Guangdong-
Maonan/SWL1536/2019(H1N1)pdm09-like virus for 
egg-based vaccines and A/Hawaii/70/2019 (H1N1)
pdm09-like virus for cell-based or recombinant-based 
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vaccines, which are 6B.1A5A viruses, harbouring addi-
tional D187A and Q189E substitutions. For influenza 
A(H3N2), WHO recommended A/HongKong/2671/2019 
(H3N2)-like virus for egg-based vaccines and A/
HongKong/45/2019 (H3N2)-like virus for cell-based or 
recombinant-based vaccines, both 3C.2a1b + T135K-B 
viruses, harbouring S137F, A138S and F193SHA substi-
tutions. For the 2020 southern hemisphere influenza 
vaccine, WHO recommended for both 2020/21 northern 
hemisphere trivalent and quadrivalent vaccines a B/
Washington/02/2019-like (B/Victoria lineage) virus (a 
three amino acid deletion virus), and additionally, a B/
Phuket/3073/2013-like (B/Yamagata lineage) virus for 
the quadrivalent vaccine [25].
The VE and antigenic studies at the end of the 2019/20 
season will help to explain the differences in age-, 
subtype- and study-specific VE estimates presented 
here. In order to be prepared for the next season in the 
northern hemisphere, we should continue to monitor 
the genetic diversity of the 2020 southern hemisphere 
influenza viruses and their influenza VE.
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